U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597395) titled 'ATRA for Management of Primary ITP' on May 13.
Brief Summary: A multicenter, randomized, double-blind placebo-controlled study to report the efficacy and safety of all-trans etinoic acid compared to placebo for the treatment of adults with corticosteriod-resistant/relapsed primary immune thrombocytopenia (ITP).
Study Start Date: May 30
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Intervention:
DRUG: all-trans retinoic acid (ATRA)
10mg twice daily x24 weeks
DRUG: Placebo
10mg twice daily x24 weeks
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Peking University People's Hospital
Information provided by (R...